Legend Biotech Corp
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more
Legend Biotech Corp (LEGN) - Total Liabilities
Latest total liabilities as of September 2025: $701.69 Million USD
Based on the latest financial reports, Legend Biotech Corp (LEGN) has total liabilities worth $701.69 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Legend Biotech Corp - Total Liabilities Trend (2017–2024)
This chart illustrates how Legend Biotech Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Legend Biotech Corp Competitors by Total Liabilities
The table below lists competitors of Legend Biotech Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Exponent Inc
NASDAQ:EXPO
|
USA | $387.18 Million |
|
S-Oil Corp
KO:010950
|
Korea | ₩16.34 Trillion |
|
Guangzhou Great Power Energy&Technology Co Ltd
SHE:300438
|
China | CN¥14.96 Billion |
|
Centerra Gold Inc
NYSE:CGAU
|
USA | $750.52 Million |
|
Henan Zhongfu Industrial Co Ltd
SHG:600595
|
China | CN¥7.55 Billion |
|
Avic Aviation High Technology Co Ltd
SHG:600862
|
China | CN¥2.88 Billion |
|
Enagás S.A
PINK:ENGGF
|
USA | $5.43 Billion |
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
USA | $399.91 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Legend Biotech Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.69 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Legend Biotech Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Legend Biotech Corp (2017–2024)
The table below shows the annual total liabilities of Legend Biotech Corp from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $629.61 Million | +5.42% |
| 2023-12-31 | $597.24 Million | +1.80% |
| 2022-12-31 | $586.65 Million | +65.95% |
| 2021-12-31 | $353.52 Million | +189.13% |
| 2020-12-31 | $122.27 Million | -70.22% |
| 2019-12-31 | $410.58 Million | -2.33% |
| 2018-12-31 | $420.40 Million | +85.59% |
| 2017-12-31 | $226.53 Million | -- |